VTGN VistaGen Therapeutics

VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021

VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will host a conference call and webcast, reporting its financial results for the quarter ended September 30, 2021 and reviewing recent accomplishments and anticipated upcoming milestones, on Wednesday, November 10, 2021 at 5:00 p.m. Eastern Time.

Event: VistaGen Therapeutics Fiscal Year 2022 Second Quarter Financial Results and Recent Developments Conference Call and Webcast

Date: Wednesday, November 10, 2021

Time: 5:00 p.m. Eastern Time

U.S. Dial-in (Toll Free): 1-877-407-9716

International Dial-in (Toll): 1-201-493-6779

Conference ID: 13724394

Webcast:

A live audio webcast of the conference call will be available. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Wednesday, November 10, 2021. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 13724394.

About VistaGen

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's CNS drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visit  and connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company Contacts

Media:

Mark McPartland

Vice President, Corporate Development

Phone: (650) 577-3606

Email:

Christy Curran

Sam Brown Inc.

Phone: (615) 414-8668

Email:    

Investor:

Mark Flather

Vice President, Investor Relations

Phone: (650) 577-3617

Email:



EN
04/11/2021

Underlying

VTGNVistaGen Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VistaGen Therapeutics

 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen to Participate in the Maxim Group Healthcare Virtual Conferen...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in the Healthcare Virtual Conference presented by Maxim Group LLC taking place June 20 – 22, 2023 virtually on the M-Vest platform. Maxim Group Healthcare Virtual Conference 2023 Fireside Chat Date and Time: Thursday, June 22, 2023 at 1:30 p.m. Eastern T...

June 16, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces European Patent Office Intention to Grant New PH80 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company’s five rapid-onset investigational neuroactive pherine therapeutics. The patent claims also include treatment administered at the onset of migraine symptoms an...

June 13, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces Positive Results from Exploratory Phase 2A Study of...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the acute treatment of hot flashes (vasomotor symptoms) in women diagnosed with menopausal hot flashes. The randomized, double-blind, placebo-contro...

June 7, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen to Present at Jefferies 2023 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference taking place June 7 – 9, 2023 in New York City, NY. Jefferies 2023 Global Healthcare Conference Details Fireside Chat Date and Time: Friday, June 9 at 9:30 a.m. Eastern Time Location: M...

June 6, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces Stockholder-Approved Reverse Stock Split

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors. Vistagen common stock will begin trading on a split-adjusted basis at the opening of trading on the Nasdaq Capital Market on Wednesday, June 7, 20...

June 6, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch